Alterity Therapeutics Limited - American Depositary Shares (ATHE)

Competitors to Alterity Therapeutics Limited - American Depositary Shares (ATHE)

Acorda Therapeutics, Inc.

Acorda Therapeutics is a biotechnology company that develops therapies for neurological disorders. Although Alterity Therapeutics' scope includes a broader range of neurodegenerative diseases, Acorda's established products and ongoing clinical trials keep them competitive. Acorda's established market presence and experience in navigating the regulatory landscape may offer them a competitive advantage over Alterity in terms of market access and commercialization.

Axovant Gene Therapies Ltd.

Axovant Gene Therapies focuses on developing innovative gene therapies for neurological diseases, similar to Alterity Therapeutics, which targets neurodegenerative conditions. Both companies are exploring novel treatment methods, but Axovant's recent advancements in gene therapy could provide them with a significant edge in terms of technological capabilities and novel approaches to treatment. Their higher level of financing and strategic partnerships also enhance their potential for drug development.

Ionis Pharmaceuticals, Inc. 

Ionis Pharmaceuticals concentrates on RNA-targeted drug discovery, with a focus on neurodegenerative diseases and conditions such as ALS. This positions them as direct competitors to Alterity Therapeutics, especially when both companies target similar neurological disorders. Ionis holds a competitive advantage due to their extensive patent portfolio and established therapies that are already in the market, which provide them with a strong revenue stream to reinvest in further research and development.

NeuroRx, Inc. 

NeuroRx focuses on developing therapies for neurodegenerative diseases and psychiatric disorders. This creates a competitive landscape as both NeuroRx and Alterity Therapeutics eye similar markets. However, NeuroRx's existing collaborations and partnerships for clinical trials may grant them more immediate competitive advantages in accessing clinical data and developing relationships with key opinion leaders in the neurological field.

Sarepta Therapeutics, Inc. 

Sarepta Therapeutics specializes in developing precision genetic medicine to treat rare diseases, including those affecting the nervous system. While Alterity Therapeutics focuses on neurodegenerative disorders, the overlap in target patient populations creates direct competition. Sarepta has established itself as a leader in rare genetic diseases with an extensive product pipeline and successful therapies, giving them a competitive advantage in research and development resources.